Novo Nordisk A/S announced the completion of a share repurchase program that began on February 6, 2024, repurchasing 2,423,000 B shares for a total of DKK 2.1 billion by April 30, 2024. This event underscores the company's commitment to returning value to shareholders following its investment strategy, and total shares held as treasury have reached 3,945,719, representing 0.1% of its share capital.